

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. <b>RLL-262US</b>	
In Re Application Of: <b>GOGIA et al.</b>						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/518,972		Unknown	26815	Unknown	2913	
Title: <b>PROCESS FOR THE PREPARATION OF ROBUST FORMULATIONS OF VALACYCLOVIR HYDROCHLORIDE TABLETS</b>						
<div style="text-align: center;"> <p>Address to:</p> <p><b>Commissioner for Patents</b>  <b>P.O. Box 1450</b>  <b>Alexandria, VA 22313-1450</b></p> </div> <div style="text-align: center; margin-top: 10px;"> <p><b>37 CFR 1.97(b)</b></p> </div> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <div style="text-align: center; margin-top: 20px;"> <p><b>37 CFR 1.97(c)</b></p> </div> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <div style="margin-left: 40px; margin-top: 10px;"> <p><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center; margin-top: 10px;"><b>OR</b></p> <p><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p> </div>						

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

RLL-262US

In Re Application: GOGIA et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/518,972		Unknown	26815	Unknown	2913

Title: PROCESS FOR THE PREPARATION OF ROBUST FORMULATIONS OF VALACYCLOVIR  
HYDROCHLORIDE TABLETS

## Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

## Certificate of Transmission by Facsimile\*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_)

(Date) \_\_\_\_\_

Signature \_\_\_\_\_

Typed or Printed Name of Person Signing Certificate \_\_\_\_\_

Certificate of Mailing by ~~First Class Mail~~ <sup>Express</sup>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as ~~first class~~ <sup>Express</sup> mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on \_\_\_\_\_

(Date) 1/18/2006

Signature of Person Mailing Correspondence \_\_\_\_\_

Christine Kenedy

Typed or Printed Name of Person Mailing Certificate \_\_\_\_\_

\*This certificate may only be used if paying by deposit account.

Dated: January 18, 2006

George E. Heibel  
Reg. No. 42,648

CUSTOMER NO. 26815

CC:

**INFORMATION DISCLOSURE CITATION**

Docket No.: RLL-262US

Serial No.: 10/518,972

Applicants: **●** GIA *et al.*

Filed: 12/21/2004

Group:

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,957,924	9/18/1990	Beauchamp	514	262	
	A2	5,879,706	3/9/1999	Carter <i>et al.</i>	424	464	
	A3	6,107,302	8/22/200	Carter <i>et al.</i>	514	262	

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO	
	B1	WO 96/22082	7/25/1996	PCT	A61K	9/20		
	B2	WO 96/22291	7/25/1996	PCT	C07D	473/00		
	B3	WO 96/32097	10/17/1996	PCT	A61K	9/20		
	B4	WO 97/25989	7/24/1997	PCT	A61K	31/52		
	B5	WO 03/022209	3/20/2003	PCT	A61K			
	B6	EP 0 308 065	3/22/1989	EPO	C07D	473/18		

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	Beauchamp et al., "Amino acid ester prodrugs of acyclovir", <i>Antiviral Chemistry and Chemotherapy</i> , 3(3):157-164 (1992)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.